Highlights Newsletter 2

This newsletter presents you the following key sessions:

1. Podcast with Dr. Zev Wainberg about the randomised, double-blind, placebo-controlled phase II study of
    bemarituzumab combined with modified FOLFOX6 in first-line treatment of advanced gastro/
    gastroesophageal junction adenocarcinoma

2. Circulating tumour DNA as a biomarker for recurrence in colorectal cancer

3. Cetuximab maintenance for RAS wild-type metastatic colorectal cancer

4. Ivosidenib induces an overall survival benefit in patients with IDH1-mutant advanced cholangiocarcinoma

5. Preoperative modified FOLFIRINOX shows efficacy as a reference regimen for future trials in borderline
    resectable adenocarcinoma of the pancreas